Therapixel announces launch of prospective study on the utility of Artificial Intelligence (AI) as part of second reading breast cancer screening mammograms

The first French prospective clinical study to evaluate the contribution of AI in the second reading of screening mammograms.

Therapixel releases a new version of MammoScreen® that leverages prior exams for better accuracy

For the first time, an AI-based decision support software for breast cancer detection uses patient’s prior exams to refine its prediction of malignancy

Therapixel announces close of 15 M€ series B financing to deploy MammoScreen® 2D/3D

The Company will accelerate the commercial deployment of its Artificial Intelligence reading solution for 2D/3D mammography, with a focus on the United States

Therapixel receives FDA clearance for use of its AI-based breast cancer screening software MammoScreen® on Digital Breast Tomosynthesis

AI-powered reading aid for screening 2D & 3D mammography improves Radiologists’ performance in cancer detection


Therapixel and RAD-AID International Announce Breast Imaging AI Collaboration for Global Health

The collaboration donates and supports AI for making breast cancer screening more accessible and available in impoverished regions of the world

MammoScreen received 510(k) clearance

Therapixel receives FDA 510(k) clearance for MammoScreen™

AI-powered reading aid for screening mammography improves Radiologists’ performance in cancer detection